Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
Monte Rosa Therapeutics presented preclinical data at the AACR 2026 Annual Meeting showcasing the potential of MRT-55811, a first-in-class cyclin E1 (CCNE1)-directed molecular glue degrader. The compound demonstrated strong tumor regression in CCNE1-amplified models of ovarian, breast, and gastric cancers with superior selectivity and reduced off-t…